<DOC>
	<DOC>NCT02693691</DOC>
	<brief_summary>The purpose of this study is to characterize the use of the CardioMEMS™ HF System when used in a real-world setting.</brief_summary>
	<brief_title>CardioMEMS European Monitoring Study for Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Indicated to receive a CardioMEMS sensor implant per the CardioMEMS™ HF System User's Manual &gt; 18 years of age Diagnosis of New York Heart Association (NYHA) Class III Heart Failure at the time of sensor implantation Hospitalization for worsening HF, as defined in the protocol, within 12 months prior to the CardioMEMS HF System implant Subjects with reduced Left Ventricular Ejection Fraction (LVEF) must be on stable Guideline Directed Medical Therapy (GDMT) as tolerated Written informed consent obtained from subject Known coagulation disorders or inability to take two types of blood thinning medications for one month after the sensor is implanted Subjects deemed a candidate for transplant, Ventricular Assist Device, or hospice care in the next 12 months or are otherwise not expected to be able to complete the study follow up</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>